WCLC / IASLC 2025

Who moved the needle at WCLC / IASLC 2025

Top physician voices ranked by impressions. Institutional / media accounts excluded.

Stephen V Liu, MD

@stephenvliu

94.1K imp · 18 tweets

Hidehito HORINOUCHI

@hhorinouchi

61.4K imp · 13 tweets

Patrick Forde

@fordepatrick

55.2K imp · 9 tweets

Jarushka Naidoo

@drjnaidoo

44.2K imp · 10 tweets

Dr. Antonio Calles 🫁🚭

@tony_calles

42.0K imp · 5 tweets

Dr Amol Akhade

@suyogcancer

41.6K imp · 5 tweets

Drew Moghanaki

@drewmoghanaki

36.8K imp · 5 tweets

Charu Aggarwal, MD, MPH,

@charuaggarwalmd

27.2K imp · 5 tweets

Brendon Stiles

@brendonstilesmd

24.0K imp · 4 tweets

Bartomeu Massuti

@bmassutis

23.0K imp · 10 tweets

Dr. Estela Rodriguez

@latinamd

18.0K imp · 18 tweets

Tejas Patil

@tejaspatilmd

16.9K imp · 8 tweets

Top trials discussed

What KOLs were talking about

Click any theme to see the top tweets that matched.

🧲 Bispecifics 25 tweets · 123.8K imp ▾

Dr Amol Akhade

@suyogcancer

🚨 Trials to Watch – WCLC 2025 🚨 🔑 Plenary LBAs: FLAURA2: Osimertinib + Chemo (OS update) Aumolertinib + Chemo (EGFRm NSCLC) HARMONi-A: Ivonescimab + Chemo vs Chemo ARROS-1: Zidesamtinib (ROS1+) CheckMate 816: Neoadjuvant Nivolumab (OS) EA5181: Durvalumab + CRT in Stage III

21.9K impressions

Stephen V Liu, MD

@stephenvliu

Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?

21.4K impressions

Charu Aggarwal, MD, MPH, FASCO

@charuaggarwalmd

Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to

16.9K impressions

Benjamin Besse

@benjaminbessemd

EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25

15.0K impressions

Dr Amol Akhade

@suyogcancer

Is this the end ? Or beginning? For ivonescimab. @Alfdoc2 @StephenVLiu @BalazsHalmosMD @RManochakian @OncBrothers @OncoAlert @chulkimMD @dr_yakupergun

7.1K impressions

Dr Amol Akhade

@suyogcancer

HARMONi-A and the Curious Case of OS: From “Negative Drift” to a Positive Surprise One of the most anticipated stories at #WCLC25 will be the HARMONi-A trial of ivonescimab (PD-1/VEGF bispecific) in EGFR-mutated, TKI-resistant NSCLC. Why? Because the overall survival (OS) curve

7.0K impressions

🛡️ Immunotherapy 15 tweets · 72.2K imp ▾

Stephen V Liu, MD

@stephenvliu

Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?

21.4K impressions

Charu Aggarwal, MD, MPH, FASCO

@charuaggarwalmd

Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to

16.9K impressions

Rami Manochakian MD, FASCO Can

@rmanochakian

🔥🚨@OncoAlert HOT OFF THE PRESS. Just published @TheLancetOncol In conjunction with presentation @IASLC #WCLC25 Impressive Results of: ⭐️#DeLLphi303: Phase 1b trial of: #Tarlatamab + anti-PD-L1 as #maintenance Tx after 1st line Chemo/IO in ES #SmallCell #LungCancer

8.9K impressions

Dr Amol Akhade

@suyogcancer

HARMONi-A and the Curious Case of OS: From “Negative Drift” to a Positive Surprise One of the most anticipated stories at #WCLC25 will be the HARMONi-A trial of ivonescimab (PD-1/VEGF bispecific) in EGFR-mutated, TKI-resistant NSCLC. Why? Because the overall survival (OS) curve

7.0K impressions

Patrick Forde

@fordepatrick

Great thread, proud of @Joshua_Reuss & many pt/colleagues in bringing to fruition this neoadjuvant immunotherapy trial for mesothelioma w cutting edge liquid biopsy data from @ValsamoA , now open access @NatureMedicine ! @curemeso @cancertrials_ie #WCLC25

4.7K impressions

Dr Amol Akhade

@suyogcancer

Data that we all were waiting for (ivonescimab + chemo post-osimertinib): HARMONi-A (WCLC25) – ivonescimab (PD-1/VEGF bispecific) + chemo vs chemo after 3rd-gen EGFR-TKI progression mPFS 6.8 vs 4.4 mo (HR 0.52, p<0.001) ORR 44.7% vs 34.2% Intracranial PFS benefit (HR 0.34 in BM

4.2K impressions

🧬 ctDNA / Liquid Biopsy 7 tweets · 30.8K imp ▾

Hidehito HORINOUCHI

@hhorinouchi

☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Tumor Informed Whole Genome Based MRD for Predicting Recurrence in Early-Stage Resectable NSCLC 🎯Signatera by @NateraOncology 🎯MRD+ RFS (HR: 20, 95% CI: 1.8-230) 🎙️ Dr. Gaston Becharano @OncoAlert @Larvol @IASLC

7.8K impressions

Jarushka Naidoo

@drjnaidoo

#WCLC25 Presidential Superb FLAURA2 OS discussion by @danieltanmd, main questions: - combo may ⬆️likelihood of long-term response? - clinical/molec/ctDNA factors relevant - refinement needs complex integration of factors Extremely elegant slides, I plan to use 😃 @IASLC #LCSM

7.6K impressions

Patrick Forde

@fordepatrick

Great thread, proud of @Joshua_Reuss & many pt/colleagues in bringing to fruition this neoadjuvant immunotherapy trial for mesothelioma w cutting edge liquid biopsy data from @ValsamoA , now open access @NatureMedicine ! @curemeso @cancertrials_ie #WCLC25

4.7K impressions

Hidehito HORINOUCHI

@hhorinouchi

☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC 🎯Preoperative ctDNA detection rates in p-stage IA and IB were 33% and 71%, respectively 🎙️ Dr. Natasha Leighl @OncoAlert @Larvol @IASLC

4.4K impressions

Shankar Siva

@_shankarsiva

#WCLC2025 #LCSM neoadura (neoadjuvant osimertinib) - MRD analysis suggests that ctDNA can be prognostic and predictive for outcome and path response in eGFR mutated #lungcancer?

3.5K impressions

Charu Aggarwal, MD, MPH, FASCO

@charuaggarwalmd

CtDNA MRD presentation today from #NeoADAURA trial demonstrates that: 🔹 ultra sensitive assays can detect higher proportion of pts w/ MRD 🔹 as we know, these assays are prognostic at baseline 🔹 clearance correlates with MPR @IASLC #WCLC25

1.7K impressions

📊 MRD 6 tweets · 23.0K imp ▾

Hidehito HORINOUCHI

@hhorinouchi

☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Tumor Informed Whole Genome Based MRD for Predicting Recurrence in Early-Stage Resectable NSCLC 🎯Signatera by @NateraOncology 🎯MRD+ RFS (HR: 20, 95% CI: 1.8-230) 🎙️ Dr. Gaston Becharano @OncoAlert @Larvol @IASLC

7.8K impressions

Hidehito HORINOUCHI

@hhorinouchi

☑️#WCLC25 #LCSM Oral Abstract🆙 🔥NeoADAURA MRD Analysis 🎯NeXT Personal® @PersonalisInc 🌟71% were MRD+ / 30% COBAS-detected plasma EGFRm 🎯EFS (HR MRD - vs +, 0.24, 95% CI 0.07, 0.80) 🎙️ Dr. Collin M Blakely @OncoAlert @Larvol @IASLC #Liquidbiopsy

5.0K impressions

Hidehito HORINOUCHI

@hhorinouchi

☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC 🎯Preoperative ctDNA detection rates in p-stage IA and IB were 33% and 71%, respectively 🎙️ Dr. Natasha Leighl @OncoAlert @Larvol @IASLC

4.4K impressions

Shankar Siva

@_shankarsiva

#WCLC2025 #LCSM neoadura (neoadjuvant osimertinib) - MRD analysis suggests that ctDNA can be prognostic and predictive for outcome and path response in eGFR mutated #lungcancer?

3.5K impressions

Charu Aggarwal, MD, MPH, FASCO

@charuaggarwalmd

CtDNA MRD presentation today from #NeoADAURA trial demonstrates that: 🔹 ultra sensitive assays can detect higher proportion of pts w/ MRD 🔹 as we know, these assays are prognostic at baseline 🔹 clearance correlates with MPR @IASLC #WCLC25

1.7K impressions

Dr. Estela Rodriguez

@latinamd

#WCLC25 Day 3 Presidential Symposium Excellent discussion by Dr Tina Cascone @MDAndersonNews on #NADIMII results highlighting scientific rationale and gaps in understanding (role of MRD, understanding patterns of recurrence and escalation/ de-escalation strategies) #lcsm @IASLC

530 impressions

💉 ADCs 3 tweets · 19.7K imp ▾

Benjamin Besse

@benjaminbessemd

EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25

15.0K impressions

Hidehito HORINOUCHI

@hhorinouchi

☑️#WCLC25 #LCSM Oral Abstract🆙 🔥TROPION-Lung01 🔥Intracranial Efficacy of Datopotamab Deruxtecan (Dato-DXd) 🎯Intracranial ORR 37.5% (95% CI, 15.2-64.6) 🎙️ Dr. Elvire Pons-Tostivint @OncoAlert @Larvol @IASLC

4.1K impressions

Tejas Patil

@tejaspatilmd

OA10.01 Intracranial Efficacy of Datopotamab Deruxtecan (Dato-DXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01 TROPION-Lung5 showed that Dato-Dxd has activity in patients with sensitizing EGFR mutations. Phase 2 ORCHARD looked at combination of osimertinib +

641 impressions

⚡ KRAS / RAS 1 tweets · 4.0K imp ▾

Eli Lilly and Company

@elilillyandco

KRAS are the most common mutations in non-small cell lung cancer (#NSCLC), with G12C mutations present in ~13% of cases. The @FDA granted Breakthrough Therapy designation for our investigational treatment. Updated data coming at #WCLC25. Learn more:

4.0K impressions

🤖 AI in Oncology 1 tweets · 371 imp ▾

Dr. Nagla Abdel Karim

@naglaakarimmd

⁦@HoudaBahig⁩ Discussing all about AI & novel radiation oncology updates here ⁦@IASLC⁩ #WCLC25

371 impressions

Trials discussed at WCLC / IASLC 2025

Ranked by total impressions. Click through to the full KOL Pulse trial profile.

The 10 tweets that defined WCLC / IASLC 2025

Physician voices only, ranked by impressions. Click any card to open the original on X.

Dr Amol Akhade

@suyogcancer

#1

🚨 Trials to Watch – WCLC 2025 🚨 🔑 Plenary LBAs: FLAURA2: Osimertinib + Chemo (OS update) Aumolertinib + Chemo (EGFRm NSCLC) HARMONi-A: Ivonescimab + Chemo vs Chemo ARROS-1: Zidesamtinib (ROS1+) CheckMate 816: Neoadjuvant Nivolumab (OS) EA5181: Durvalumab + CRT in Stage III

21.9K impressions

Stephen V Liu, MD

@stephenvliu

#2

Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?

21.4K impressions

Drew Moghanaki

@drewmoghanaki

#3

“Resectability depends on a state of mind” - @Mat_Guc …and society perspectives #WCLC25

21.3K impressions

Dr. Antonio Calles 🫁🚭

@tony_calles

#4

💥 Just @NEJM published OS data from MARIOOSA vs presented FLAURA-2 data at @IASLC #WCLC25 Survival of intensification strategy in 1L EGFR lung cancer. Both works, different ⚠️side effects, and $$$$. Pick your winner. #LCSM 🥊 FLAURA-2 vs MARIPOSA

20.8K impressions

Patrick Forde

@fordepatrick

#5

Surgical outcomes correlation with 5 year survival with neoadj chemo IO for lung cancer in CheckMate 816 presented by the legendary Prof. @t_mitsudomi #WCLC25 overall v good outcomes, remarkably so for pts with pneumonectomy #LCSM

19.4K impressions

Jarushka Naidoo

@drjnaidoo

#6

✨ Welcome to #WCLC25! ✨ From your Co-Chairs 🇮🇪🇨🇭🇮🇹🇪🇸may this week spark bold ideas, meaningful connections, and new horizons in lung cancer care Here’s to a week of science & collaboration, in every session @IASLC @NReguart @IsaOpitz @UmbertoMalapel1 @DrJNaidoo #LCSM

19.4K impressions

Stephen V Liu, MD

@stephenvliu

#7

Dr. @dplanchard at #WCLC25 with highly anticipated Presidential Plenary presentation with OS results from FLAURA2: first line chemo + osimertinib improves OS from 37.6 to 47.5m, HR 0.77, 4y OS rate 41% to 49%. Benefit seen across subgroups. Strong results - similar to MARIPOSA.

19.1K impressions

Charu Aggarwal, MD, MPH, FASCO

@charuaggarwalmd

#8

Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to

16.9K impressions

Brendon Stiles

@brendonstilesmd

#9

Herculean effort EA5181 investigators - unfortunately confirmed no benefit w/ concurrent ICI w/ CRT for patients w/ stage III NSCLC. We need more innovative trials in this space- -induction chemo/ICI? -combo of novel agents post CRT? -individualized rx assignment? #WCLC25

15.8K impressions

Benjamin Besse

@benjaminbessemd

#10

EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25

15.0K impressions